7.03
3.53%
0.24
After Hours:
6.98
-0.05
-0.71%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $7.03, with a volume of 1.67M.
It is up +3.53% in the last 24 hours and up +12.84% over the past month.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$6.79
Open:
$6.76
24h Volume:
1.67M
Relative Volume:
0.78
Market Cap:
$499.63M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-4.3129
EPS:
-1.63
Net Cash Flow:
$-71.49M
1W Performance:
-4.48%
1M Performance:
+12.84%
6M Performance:
-3.70%
1Y Performance:
+156.57%
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Altimmune Inc Stock (ALT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
Jan-24-24 | Initiated | Goldman | Neutral |
Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
Dec-01-22 | Initiated | Goldman | Buy |
Dec-29-21 | Resumed | Jefferies | Buy |
Jun-02-21 | Initiated | H.C. Wainwright | Buy |
Feb-11-21 | Initiated | Guggenheim | Buy |
Dec-14-20 | Initiated | Jefferies | Buy |
Nov-12-20 | Reiterated | B. Riley Securities | Buy |
Sep-25-20 | Initiated | B. Riley FBR | Buy |
Aug-14-20 | Initiated | Evercore ISI | Outperform |
Jul-31-20 | Initiated | Piper Sandler | Overweight |
Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
Feb-24-20 | Resumed | ROTH Capital | Buy |
Jul-19-19 | Initiated | ROTH Capital | Buy |
Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune (ALT) to Release Quarterly Earnings on Tuesday - MarketBeat
Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss - MSN
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - StockTitan
Thinking about buying stock in Minim, Aurora Innovation, Altimmu - GuruFocus.com
Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide - RTTNews
Altimmune (NASDAQ:ALT) Trading Up 7%Here's What Happened - MarketBeat
Altimmune (ALT) Price Target Increased by 9.39% to 19.53 - MSN
Regulatory And Clinical Catalysts Ahead For Altimmune (NASDAQ:ALT) - Seeking Alpha
When (ALT) Moves Investors should Listen - Stock Traders Daily
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: C - GuruFocus.com
Altimmune Jumps 66% After Positive Results for Its Obesity Drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Receives $18.80 Average Target Price from Brokerages - MarketBeat
SG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
State Street Corp's Strategic Reduction in Altimmune Inc Holdings - Yahoo Finance
Altimmune, Inc. (ALT): A Bull Case Theory - MSN
Exchange Traded Concepts LLC Has $1.33 Million Position in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Millennium Management LLC Increases Stake in Altimmune Inc - Yahoo Finance
Altimmune (NASDAQ:ALT) Trading Up 10.7%Should You Buy? - MarketBeat
Learn to Evaluate (ALT) using the Charts - Stock Traders Daily
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024 - The Manila Times
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Where are the Opportunities in (ALT) - Stock Traders Daily
Consider Buying Potential Takeover Target Altimmune (NASDAQ:ALT) - Seeking Alpha
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference - The Manila Times
Altimmune completes enrollment for MASH treatment trial By Investing.com - Investing.com South Africa
Altimmune completes enrollment for MASH treatment trial - Investing.com India
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) - The Manila Times
Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis - Marketscreener.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Profund Advisors LLC Sells 94,081 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Wall Street SWOT: Altimmune stock rides wave of promising obesity drug data - Investing.com
Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Altimmune Inc [ALT] Investment Guide: What You Need to Know - Knox Daily
Farallon Capital Management LLC Has $184,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
SEC Form FWP filed by Alta Global Group Limited - Quantisnow
How the (ALT) price action is used to our Advantage - Stock Traders Daily
Unique Fabricating (NYSEAMERICAN:UFAB) Trading Down 17.6% - Defense World
StockWatch: FDA Surprise Lifts Expectations for Applied’s Govorestat - Genetic Engineering & Biotechnology News
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects (NASDAQ:ALT) - Seeking Alpha
Altimmune (NASDAQ:ALT) Trading Up 3.7% - MarketBeat
Milan Fashion Week: At Gucci, making fashion wearable - CNA Luxury
The Best Celebrity Shoes at Gucci’s Spring 2025 Show in Milan: Kirsten Dunst, Lucky Blue Smith, Nara Smith and More - Footwear News
"Commit To It and Do It": Mel and Lyas Gather the Girls for a Gucci SS25 Debrief - Interview
Take a look at celebrities' outfits for Milan Fashion Week's Gucci show - Marca English
Sabato swings into the sixties: What went down at Gucci SS25 - Dazed
TikTok Star Nara Smith Stuns at Gucci’s Spring 2025 Show in Patent Leather Signoria Slingback Pumps at Milan Fashion Week - Yahoo Entertainment
Applied Therapeutics stock surges after FDA update - The Pharma Letter
Altimmune (NASDAQ:ALT) Trading Down 4.5% - MarketBeat
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club - The Motley Fool
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Drutz David | Director |
Aug 19 '24 |
Sale |
6.90 |
16,011 |
110,547 |
41,958 |
Roberts M Scot | Chief Scientific Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
44,990 |
Roberts M Scot | Chief Scientific Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
39,016 |
Harris Matthew Scott | Chief Medical Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
55,965 |
Harris Matthew Scott | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
49,991 |
Garg Vipin K | President and CEO |
Feb 02 '24 |
Option Exercise |
0.00 |
18,950 |
0 |
300,404 |
Garg Vipin K | President and CEO |
Feb 01 '24 |
Option Exercise |
0.00 |
16,545 |
0 |
288,767 |
Roberts M Scot | Chief Scientific Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
29,699 |
Harris Matthew Scott | Chief Medical Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
43,277 |
Garg Vipin K | President and CEO |
Jan 30 '24 |
Option Exercise |
0.00 |
26,775 |
0 |
276,030 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):